RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer

BACKGROUND: Currently, the prognosis for metastatic colorectal cancer (mCRC) still remains poor. The management of mCRC has become manifold because of the varied advances in the systemic and topical treatment approaches. For patients with limited number of metastases, radical local therapy plus syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kun, Chen, Yajie, Zhang, Zhiyuan, Wu, Ruiyan, Zhou, Menglong, Yang, Wang, Wan, Juefeng, Shen, Lijun, Zhang, Hui, Wang, Yan, Han, Xu, Wang, Jiazhou, Zhang, Zhen, Xia, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568524/
https://www.ncbi.nlm.nih.gov/pubmed/37842200
http://dx.doi.org/10.1093/gastro/goad063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568524/
https://www.ncbi.nlm.nih.gov/pubmed/37842200
http://dx.doi.org/10.1093/gastro/goad063

Ejemplares similares